0000000000011320

AUTHOR

Giuseppe Tarantino

0000-0001-8102-6293

showing 22 related works from this author

Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature

2010

Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15% of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as “probable” cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n = 100) and sera from patients with other chronic liver diseases (n = 104) th…

AdultMaleAnti-nuclear antibodyNuclear dotsPBCSerologyAnticorpo antimitocondrio cirrosi biliare primitivaPrimary biliary cirrhosisAntigenparasitic diseasesHumansImmunology and AllergyMedicineskin and connective tissue diseasesAgedAutoantibodiesAged 80 and overbiologyLiver Cirrhosis Biliarybusiness.industryAutoantibodyIIfGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesMitochondriaImmunologybiology.proteinFemaleAntibodybusinessClinical Reviews in Allergy & Immunology
researchProduct

Hematopoietic Peripheral Circulating Blood Stem Cells As an Independent Marker of Good Transfusion Management in Patients with Beta-Thalassemia

2015

Abstract Aim Aim of the current study was to prospectively evaluate the potential role of peripheral circulating CD34+ stem cells as new independent marker of appropriate hemopoietic balance in patients with thalassemia major and intermedia. Materials and methods Peripheral blood samples from patients with thalassemia major (TM) and intermedia (TI) were drawn. Peripheral circulating CD34+ stem cells, CF-GEMM, CFU-GM and BFU-GM were assayed with monoclonal antibodies for CD34 and clonogenic tests, according to standard procedures and ISHAGE method (BD stem cell enumeration kit, Becton Dickinson; H4434, Stem Cell Technology). Demographic and clinical data were recorded from each enrolled subj…

medicine.medical_specialtybusiness.industryThalassemiamedicine.medical_treatmentImmunologySplenectomyCD34Becton dickinsonBeta thalassemiaCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyHaematopoiesisInternal medicineCirculating Hematopoietic stem cells beta-thalassemiatrasfusionmedicineStem cellClonogenic assaybusinessBlood
researchProduct

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

2018

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter def…

CyclopropanesLiver CirrhosisMaleCirrhosis;Dasabuvir;Elderly;Ombitasvir;ParitaprevirCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged; 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy; Combination; GenotypeParitaprevirCirrhosis Dasabuvir Elderly Ombitasvir Paritaprevir Microbiology (medical) Infectious DiseasesCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; Genotype; Microbiology (medical); Infectious DiseasesHepacivirusGastroenterologychemistry.chemical_compound0302 clinical medicineElderly2-Naphthylamine80 and overMedicineAnilides030212 general & internal medicineChronicAged 80 and overSulfonamidesDasabuvirValineGeneral MedicineHepatitis CHepatitis CTreatment OutcomeInfectious DiseasesCirrhosisCombination030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleDasabuvirMacrocyclic CompoundCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Microbiology (medical); Infectious Diseasesmedicine.drugHumanMicrobiology (medical)medicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicSettore MED/12 - GASTROENTEROLOGIALiver CirrhosiSulfonamideAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinHumansDecompensationUracilAgedHepatitisAntiviral AgentCirrhosiHepaciviruRitonavirbusiness.industryRibavirinSettore MED/09 - MEDICINA INTERNAAnilideBiomarkerHepatitis C Chronicmedicine.diseaseCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; GenotypeOmbitasvirOmbitasvirchemistryParitaprevirCarbamateRitonavirCarbamatesbusinessBiomarkers
researchProduct

A new p65 isoform that bind the glucocorticoid hormone and is expressed in inflammation liver diseases and COVID-19

2021

AbstractInflammation is a physiological process whose deregulation causes some diseases including cancer. Nuclear Factor kB (NF-kB) is a family of ubiquitous and inducible transcription factors, in which the p65/p50 heterodimer is the most abundant complex, that play critical roles mainly in inflammation. Glucocorticoid Receptor (GR) is a ligand-activated transcription factor and acts as an anti-inflammatory agent and immunosuppressant. Thus, NF-kB and GR are physiological antagonists in the inflammation process. Here we show that in mice and humans there is a spliced variant of p65, named p65 iso5, which binds the corticosteroid hormone dexamethasone amplifying the effect of the glucocorti…

MaleCOVID-19.Molecular biologyGene ExpressionDexamethasoneHepatitisMiceGlucocorticoid receptorAdrenal Cortex HormonesProtein IsoformsNF-kBMultidisciplinaryLiver DiseasesQLiver NeoplasmsRNF-kappa BMiddle AgedLiverMedicineFemalemedicine.symptomliver diseaseTranscriptionNFKB P65iso5 inflammationGlucocorticoidmedicine.drugAdultGene isoformCarcinoma HepatocellularScienceImmunologyInflammationBiologyGlucocorticoid ReceptorArticleReceptors GlucocorticoidmedicineAnimalsHumansGlucocorticoidsTranscription factorDexamethasoneInflammationSARS-CoV-2p65 isoformTranscription Factor RelAWild typeCOVID-19Mice Inbred C57BLAlternative SplicingSettore BIO/18 - GeneticaGene Expression RegulationLeukocytes MononuclearCancer researchHormone
researchProduct

630 SERUM BLYS/BAFF LEVELS IN ACUTE HEPATITIS C PREDICT CLINICAL OUTCOME

2008

Hepatologybusiness.industryImmunologyMedicineAcute hepatitis CbusinessB-cell activating factorJournal of Hepatology
researchProduct

Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection.

2009

Summary.  B-lymphocyte stimulator/B activating factor (BLyS/BAFF) is a tumour necrosis factor-family cytokine that plays a key role in generating and maintaining the mature B-cell pool. BLyS/BAFF expression by macrophages is stimulated by interferon-γ and interleukin-10, and its serum levels are increased in chronic hepatitis C (CHC). The aim of this study was to assess serum levels of BLyS/BAFF in patients with acute hepatitis C (AHC) and correlate them with disease outcome. We studied 28 patients with AHC (14 males, mean age 59.3 ± 15 years), followed for at least 7 months since onset, comparing them with 86 CHC patients and 25 healthy blood donors (HBD). BLyS/BAFF levels were assessed at…

AdultMaleNecrosismedicine.medical_treatmentAcute hepatitis CVirusYoung AdultVirologyB-Cell Activating FactorMedicineHumansIn patientB-cell activating factorAgedAged 80 and overHepatologybusiness.industryHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CChronic infectionInfectious DiseasesCytokineImmunologyFemaleAcute hepatitis Cmedicine.symptombusinessBiomarkersJournal of viral hepatitis
researchProduct

Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1.

2008

Retinol-binding protein 4 (RBP4) is an adipocytokine associated with insulin resistance (IR). We tested serum levels of RBP4 to assess its link with steatosis in patients with genotype 1 chronic hepatitis C (CHC) or nonalcoholic fatty liver disease (NAFLD). Nondiabetic patients with CHC (n = 143) or NAFLD (n = 37) were evaluated by liver biopsy and anthropometric and metabolic measurements, including IR by the homeostasis model assessment. Biopsies were scored by Scheuer classification for CHC, and Kleiner for NAFLD. Steatosis was tested as a continuous variable and graded as absent-mild <30%, or moderate-severe > or =30%. Thirty nondiabetic, nonobese blood donors served as controls. …

AdultMalemedicine.medical_specialtyGenotypeHepatitis C virusHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologySeverity of Illness IndexInsulin resistanceRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicinesteatosisHumansRetinol-binding protein 4 .Retinol binding protein 4Settore MED/12 - GastroenterologiaHepatologybiologymedicine.diagnostic_testOdds ratioHepatologyHepatitis C ChronicMiddle Agedmedicine.diseaseFatty LiverLogistic ModelsLiverLiver biopsyImmunologybiology.proteinFemaleSteatosisRetinol-Binding Proteins PlasmaBiomarkers
researchProduct

Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review

2009

Recently several randomized trials involving exclusively HCV 2 and 3 patients have explored the possibility of reducing the duration of therapy with PEG IFNs and ribavirin to 12–16 weeks. Among these, the largest studies (ACCELERATE, NORTH-C and NORDynamIC) have failed to demonstrate, by intention-to-treat analysis, that short treatment is non-inferior to the standard duration of 24 weeks originated by phase 3 trials. Even though obtaining univocal conclusions from these studies are difficult to obtain due to some critical differences (trial design, genotypes 2/3 ratio, rate of cirrhosis at baseline, ribavirin dose, assays to detect HCV-RNA etc), all have proved that a rapid virological res…

medicine.medical_specialtyCirrhosisGenotypeHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled triallawInterferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseaseschemistryImmunologyDrug Therapy CombinationViral hepatitisbusinessmedicine.drugLiver International
researchProduct

Cryopreserved platelets: from in vitro thrombin generation potential to in vivo safety

2015

Abstract Background: Cryopreservation of platelets (PLTs) at -80°C with dimethyl sulfoxide (DMSO) can extend their shelf life up to 2 years. Cryopreserved PLTs (CRY-PLTs) are reported to have a greater in vivo hemostatic effect than liquid-stored PLTs. Aims of this study were: i. to evaluate the thrombin generation potential of buffy coat derived cryopreserved PLTs (CRY- BC PLT) in comparison with fresh buffy coat derived platelets concentrates; ii. to determine the efficacy and safety of CRY-PLTs transfusion in hematological patients with severe thrombocytopenia. Materials and methods: BC PLTs were obtained from 5 buffy coats and pooled. The final PLTs concentrates were leukoreduced by fil…

medicine.diagnostic_testP-selectinbusiness.industryImmunologyCell BiologyHematologyBuffy coatBiochemistryThromboelastographyCryopreservationAndrologyTissue factorThrombinIn vivoImmunologymedicinethrombin generation cryopreserved platelets DMSOPlateletbusinessmedicine.drug
researchProduct

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate

2017

Key Clinical Message Prompt ophthalmology evaluation and immediate imatinib suspension should be suggested at any time of tyrosine kinase inhibitor therapy in patients with visual deficit, as it may be a clinical manifestation of optic disk edema, and suspension may help in prompt recovery.

Adverse event0301 basic medicinegenetic structuresmedicine.drug_classOptic Disk EdemaLate onsetCase ReportClinical manifestationCase ReportsTyrosine-kinase inhibitor03 medical and health sciences0302 clinical medicinechronic myeloid leukemiatyrosine kinase inhibitorsmedicineIn patientAdverse effectbusiness.industryoptic disk edemaImatinibGeneral Medicineeye diseases030104 developmental biologyImatinib mesylateimatiniboptic nerve edemaAnesthesiaAdverse events030221 ophthalmology & optometrybusinessmedicine.drugClinical Case Reports
researchProduct

Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?

2005

Coeliac disease (CD) is found in 5-10% of patients with chronically abnormal liver tests and no obvious cause of liver disease. In this population the efficacy of screening for CD by anti-tissue transglutaminase (anti-tTG) may be impaired by the high rate of positive anti-tTG found in chronic liver disease.To evaluate the prevalence of coeliac disease and the role of anti-tTG in patients with non-viral, non-autoimmune chronic and no obvious cause of liver damage.Out of 2,512 consecutive patients with abnormal liver tests, 168 (118 men, 50 women; mean age 40.7 +/- 12.6 years) were defined, on the basis of clinical data and liver biopsy, as NAFLD or cryptogenic chronic hepatitis. All were tes…

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyAdolescentTissue transglutaminaseDuodenumBiopsyGastroenterologyCoeliac diseaseGTP-Binding ProteinsInternal medicineBiopsymedicineHumansMass ScreeningIn patientProtein Glutamine gamma Glutamyltransferase 2Aspartate AminotransferasesDuodenoscopyMass screeningAgedAutoantibodiesHepatitis ChronicHepatitisTransglutaminasesHepatologybiologymedicine.diagnostic_testbusiness.industryLiver DiseasesGastroenterologynutritional and metabolic diseasesAlanine TransaminaseMiddle Agedmedicine.diseasedigestive system diseasesImmunoglobulin AFatty LiverCeliac DiseaseLiverImmunoglobulin Gbiology.proteinFemaleAbnormal liverAntibodybusinessThe American journal of gastroenterology
researchProduct

Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.

2019

The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and JAK2 V617F presence. The revised IPSET-thrombosis uses three adverse variables to delineate four risk categories: age greater than 60, thrombosis history, and JAK2 V617F presence. We compared different risk models in the estimation of thrombotic risk in 191 patients with ET and the role of specific driver mutations affecting overall survival, according to thrombotic risk. …

MaleCancer ResearchEssential Thrombocythemia Myeloproliferative Thrombosis Thrombotic risk SurvivalKaplan-Meier EstimateSeverity of Illness IndexSettore MED/15 - Malattie Del SanguePrognostic score0302 clinical medicineRisk groupsRecurrenceRisk FactorsMutational statusThrombophiliaAged 80 and overIncidenceAge FactorsHematologyGeneral MedicineMiddle AgedPrognosisThrombosisOncology030220 oncology & carcinogenesisFemaleJAK2 V617FReceptors ThrombopoietinThrombocythemia EssentialAdultPoor prognosismedicine.medical_specialtyAdolescentMutation MissenseModels BiologicalRisk Assessment03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAgedRetrospective StudiesThrombotic riskbusiness.industryEssential thrombocythemiaThrombosisJanus Kinase 2medicine.diseasebusinessCalreticulin030215 immunologyFollow-Up StudiesHematological oncologyREFERENCES
researchProduct

Congenital Hepatic Fibrosis

2005

The disease presentation of autosomal recessive polycystic kidney disease (OMIM #263200, ARPKD) is highly variable and includes polycystic kidneys, pulmonary hypoplasia, and congenital hepatic fibrosis. The authors report an unusual case of ARPKD presenting with hepatosplenomegaly and cytopenia mimicking acute leukemia.

Liver CirrhosisMalePathologymedicine.medical_specialtyAdolescentPancytopeniaHepatosplenomegalyurologic and male genital diseasesPulmonary hypoplasiahemic and lymphatic diseasesmedicineHumanscytopeniaPolycystic Kidney Autosomal RecessivesplenomegalyCytopeniaAcute leukemiapolycystic kidney diseasebusiness.industryHematologymedicine.diseasePancytopeniaeye diseasesfemale genital diseases and pregnancy complicationsAutosomal Recessive Polycystic Kidney DiseaseOncologyDisease PresentationPediatrics Perinatology and Child HealthCongenital hepatic fibrosismedicine.symptomTomography X-Ray ComputedbusinessHepatomegalyJournal of Pediatric Hematology/Oncology
researchProduct

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target

2018

Blastic Plasmacytoid Dendritic Cell Neoplasm is a rare and aggressive hematological malignancy currently lacking an effective therapy. To possibly identify genetic alterations useful for a new treatment design, we analyzed by whole-exome sequencing fourteen Blastic Plasmacytoid Dendritic Cell Neoplasm patients and the patient-derived CAL-1 cell line. The functional enrichment analysis of mutational data reported the epigenetic regulatory program as the most significantly undermined (P<.0001). In particular, twenty-five epigenetic-modifiers were found mutated (e.g., ASXL1, TET2, SUZ12, ARID1A, PHF2, CHD8); ASXL1 was the most frequently affected (28.6% of cases). To evaluate the impact of …

Acute Myeloid LeukemiaBlastic plasmacytoid dendritic cell neoplasm epigenetic mutationsSkin NeoplasmsAzacitidineDecitabinePlasmacytoid dendritic cellGene mutationBiologyDecitabineBPDCNArticleEpigenesis Genetic03 medical and health sciences0302 clinical medicineHistone methylation5’-Azacytidine; Acute Myeloid Leukemia; BPDCN; Decitabine; WESmedicineHumansEpigeneticsExome sequencingRegulation of gene expressionMyeloproliferative DisordersDendritic CellsGenomicsHematology5 -AzacytidineMyeloid Neoplasms5’-AzacytidineCancer researchWES030215 immunologymedicine.drugHaematologica
researchProduct

An insight into the interaction between functionalized thermoplastic elastomer and layered double hydroxides through rheological investigations

2018

Abstract Nanocomposites based on maleated poly(styrene-(ethylene-co-butylene)-styrene) copolymer (SEBSgMA) and organo-modified layered double hydroxide (OLDH) have been formulated with the aim to investigate the effects of interfacial interactions between the grafted maleic anhydride groups of the copolymer and the OLDH nanolayers on the rheological properties of nanocomposites. The spectroscopic analysis indicates the establishment of specific polymer/nanofiller interactions, whose extent has been highlighted through morphological and rheological investigations. Specifically, oscillatory melt rheology and shear relaxation tests have been considered in order to deeply investigate the interf…

Physical propertiePolymer-matrix composites (PMCs)Materials scienceCeramics and Composite02 engineering and technologyengineering.materialNano-structure010402 general chemistry01 natural sciencesIndustrial and Manufacturing Engineeringchemistry.chemical_compoundRheologyCopolymerRheological propertieMechanics of MaterialRheological propertiesComposite materialThermoplastic elastomerNano-structures; Physical properties; Polymer-matrix composites (PMCs); Rheological properties; Ceramics and Composites; Mechanics of Materials; Mechanical Engineering; Industrial and Manufacturing EngineeringSettore CHIM/02 - Chimica Fisicachemistry.chemical_classificationNanocompositePhysical propertiesMechanical EngineeringLayered double hydroxidesMaleic anhydridePolymer021001 nanoscience & nanotechnology0104 chemical scienceschemistryNano-structuresMechanics of MaterialsengineeringCeramics and CompositesHydroxide0210 nano-technology
researchProduct

751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS

2008

Retinol binding proteinRetinol binding protein 4HepatologyBiochemistrybiologybusiness.industrybiology.proteinMedicineSteatosisbusinessmedicine.disease
researchProduct

Paroxysmal nocturnal haemoglobinuria: When delay in diagnosis and long therapy occurs

2017

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, caused by a somaticmutation in PIG-A gene that results in theabsence of CD55 and CD59, two important complement regulatory proteins. In thispaper, a case of PNH is retrospectively examined looking for clinical and laboratory features, and the entire course of the disease from the onset of the symptoms isdescribed, together with an adequate follow-up over a 7-years treatment period. Inthis case, the not specificity and the limited clinical relevance of the symptoms led to adelay in diagnosis. After thrombosis, Eculizumab therapy has been shown to be effec…

0301 basic medicineHemolytic anemiaPediatricsmedicine.medical_specialtyrenal failureParoxysmal nocturnal haemoglobinuriaparoxysmal nocturnal hemoglobinuriaCase ReportDiseaseCD5903 medical and health sciencesthrombotic eventshemic and lymphatic diseasesMedicineClinical significancebusiness.industrylcsh:RC633-647.5Bone marrow failureHematologylcsh:Diseases of the blood and blood-forming organsEculizumabEculizumabmedicine.diseaseThrombosisparoxysmal nocturnal hemoglo-binuria thrombotic events renal failure Eculizumab030104 developmental biologyParoxysmal nocturnal hemoglobinuriabusinessmedicine.drug
researchProduct

Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C.

2008

Eosinophilic infiltrate of liver tissue is described in primary cholestatic diseases, hepatic allograft rejection and drug-induced liver injury, but its significance and its implications in chronic hepatitis C are unknown. The aim of this study was to investigate the clinical significance of eosinophilic liver infiltrate in patients with chronic hepatitis C. We retrospectively evaluated 147 patients with chronic hepatitis C. The presence of eosinophilic infiltrate was investigated in liver biopsies, and a numeric count of eosinophilic leucocytes in every portal tract was assessed. An eosinophilic infiltrate of liver tissue (> or =3 cells evaluated in the portal / periportal spaces) was obse…

Liver CirrhosisMalemedicine.medical_specialtyPathologyLiver steatosisSettore MED/08 - Anatomia PatologicaChronic hepatitis CGastroenterologyFibrosisVirologyInternal medicineEosinophiliaEosinophilicHumansMedicineClinical significanceRetrospective StudiesLiver injuryHepatologymedicine.diagnostic_testbusiness.industryLiver fibrosiOdds ratioHepatitis CHepatitis C ChronicLiver biopsymedicine.diseaseEosinophilsFatty LiverInfectious DiseasesLiverLiver biopsyFemaleEosinophilic infiltrateSteatosisDrugChronic hepatitis C; Drugs; Eosinophilic infiltrate; Liver biopsy; Liver fibrosis; Liver steatosisbusiness
researchProduct

Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome

2008

Hepatologybusiness.industryImmunologyGastroenterologyMedicineAcute hepatitis CbusinessB-cell activating factor
researchProduct

Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases.

2010

Abstract Background/Aim Plasma cells infiltrate in the liver is a prototype lesion of autoimmune liver diseases. The possible role of plasma cells isotyping (IgM and IgG) in the liver in the diagnostic definition of autoimmune liver disease, and particularly in variant syndromes such as autoimmune cholangitis and the primary biliary cirrhosis/autoimmune hepatitis overlap syndrome, is less defined. Methods We analysed the clinical, serological and histological features of 83 patients with autoimmune liver disease (40 primary biliary cirrhosis, 20 autoimmune hepatitis, 13 primary sclerosing cholangitis, 4 autoimmune cholangitis and 6 overlap syndrome) compared to 34 patients with chronic hepa…

AdultMalePathologymedicine.medical_specialtyLiver kidney microsomal type 1 antibodyCholangitisBiopsyCholangitis SclerosingPlasma CellsAutoimmune hepatitisAutoimmune cholangitis Autoimmune hepatitis IgG plasma cells IgM plasma cells Immunostaining Liver biopsy Overlap syndromes Portal infiltrate Primary biliary cirrhosisSettore MED/08 - Anatomia PatologicaAutoimmune DiseasesPrimary sclerosing cholangitisSex FactorsPrimary biliary cirrhosismedicineHumansAgedAutoantibodiesHepatitisSettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testLiver Cirrhosis Biliarybusiness.industryGastroenterologyAlanine TransaminaseOverlap syndromegamma-GlutamyltransferaseMiddle AgedAlkaline Phosphatasemedicine.diseaseHepatitis CHepatitis AutoimmuneImmunoglobulin MLiverImmunoglobulin GLiver biopsyFemaleBile DuctsbusinessAnti-mitochondrial antibody
researchProduct

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with…

2017

Summary Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), …

CyclopropanesCompassionate Use TrialsLiver CirrhosisMalechemistry.chemical_compound0302 clinical medicine2-NaphthylamineHCV direct-acting antiviral mixed cryoglobulinemia RBVAnilides030212 general & internal medicineLongitudinal StudiesProspective StudiesChronicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; UracilSettore MED/12 - GastroenterologiaSulfonamidesDasabuvirHCV DAAGastroenterologyvirus diseasesValineMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CTreatment OutcomeGastroenterology; HepatologyCombinationDrug Therapy Combination030211 gastroenterology & hepatologyFemalemedicine.drugAdultmedicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicAdult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy Combination; Female; Genotype; Hepatitis C Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Hepatology; GastroenterologyHepatitis C virus genotype 1 Hepatitis C virus genotype 4 decompensated liver cirrhosis antiviral therapy dasabuvir ombitasvir paritaprevirHepatology; GastroenterologyAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinmedicineHumansDecompensationAdverse effectUracilAgedRitonavirHepatologybusiness.industryRibavirinHepatitis C ChronicVirologyOmbitasvirClinical trialchemistryParitaprevirRitonavirCarbamatesbusiness
researchProduct

Reversibility of fibrosis

2006

researchProduct